Zemvax Appoints Lee Seok-jun as New President of Bio Business Division

GemVax & Kael announced on the 3rd that it has recruited attorney Seokjun Lee, a former member of the global law firm Latham & Watkins, as the President of its Bio Business Division.

Lee Seok-jun, New President of the Bio Business Division at GemVax & Kael
[Photo by GemVax]

President Lee is a U.S. attorney who graduated from Seoul National University with a degree in Economics and from Vanderbilt University Law School. He is an expert who has provided legal advice on overall management to global companies for over 20 years. He worked at the Bank of Korea during the 1997 Asian financial crisis and later at the U.S. Securities and Exchange Commission (SEC) following the Enron scandal in 2001, experiencing major upheavals in the capital markets of both Korea and the U.S. He began his career at the U.S. Wall Street law firm Davis Polk & Wardwell in 2005 and subsequently worked at Clifford Chance, among others.

With the recruitment of President Lee, who has extensive experience and understanding of domestic and international companies, GemVax plans to concretize the commercialization strategy for GV1001, a therapeutic agent under development for neurodegenerative diseases such as Alzheimer's dementia and progressive supranuclear palsy (PSP), and actively pursue domestic and foreign investment attraction.

President Lee stated, “I have been entrusted with a key role at an important time when we must prepare the fruits of proving GV1001’s efficacy. I will devote all my capabilities to ensure smooth development, commercialization, and active investment attraction.”

This content was produced with the assistance of AI translation services.